GlassScriptPhysician profile
Veronica Sampayo
NPI 1811347875
$3,137.56
in general payments reported to CMS, 2019-2025
29 companies · $44.74 in 2025
The $44.74 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $692 · 2022: $575 · 2023: $1,251 · 2024: $574 · 2025: $44.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,870.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $350.72 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Vivus LLC | $275.28 | 2021-2024 | Pancreaze |
| Abbvie INC. | $259.69 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $240.56 | 2022-2024 | |
| Antares Pharma, INC. | $216.58 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.91 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $194.98 | 2022-2024 | |
| Novo Nordisk INC | $191.82 | 2021-2024 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $163.22 | 2022-2024 | Gvoke Hypopen |
| Abbott Laboratories | $159.21 | 2021-2024 | Freestyle Libre |
| Neurocrine Biosciences, INC. | $124.26 | 2023 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $99.95 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $85.51 | 2021 | |
| Atricure, INC. | $79.01 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $46.59 | 2024 | Veozah |
| Ascensia Diabetes Care US INC. | $41.50 | 2023 | |
| Esperion Therapeutics, INC. | $38.91 | 2021 | |
| Amgen INC. | $38.37 | 2021-2022 | |
| Clarus Therapeutics INC. | $37.20 | 2021 | |
| Dexcom, INC. | $29.35 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $23.25 | 2022 | |
| Grt US Holding, INC. | $20.73 | 2022 | |
| Recordati_rare_diseases_inc. | $20.67 | 2023 | Isturisa, Signifor Lar |
| Amneal Pharmaceuticals LLC | $16.96 | 2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.49 | 2021 | |
| Radius Health, INC. | $15.61 | 2023 | Tymlos |
| Merck Sharp & Dohme LLC | $14.99 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Sampayo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.